NEWS – CONNECTA Therapeutics

NEWS

Connecta Therapeutics receives funding to expand therapeutic indications for its FXS drug CTH120

February 03, 2022

Connecta Therapeutics, a biotechnology company that specialises in the discovery and development of new treatments for unmet central nervous system (CNS) needs, has been granted €247,577 in funding through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development…

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

September 07, 2021

CTH120, designed using artificial intelligence techniques, will start Phase I in 2022. CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases.

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

December 01, 2020

The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency. Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences.

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

December 01, 2020

The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme

CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME

September 26, 2020

Connecta Therapeutics has closed a €1.7million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have fragile X syndrome (FXS). CDTI and the biotechnology company’s founders also participated.